MedTrace Logo

Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System

NCT02097082 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-09-06

No results posted yet for this study

Summary

An evaluation of the safety and performance of the STANZA Drug-eluting Resorbable Scaffold (DRS) system for the treatment of patients with obstructive superficial femoral artery disease.

Conditions

Interventions

DEVICE

STANZA Drug-eluting resorbable Scaffold

Sponsors & Collaborators

  • 480 Biomedical

    lead INDUSTRY

Principal Investigators

  • Andrew Holden, MD · Auckland City Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-03-30
Completion
2017-05-31

Countries

  • Austria
  • Germany
  • New Zealand
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02097082 on ClinicalTrials.gov